Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Global Diabetes & Obesity Drug Development Pipeline Review 2016: T2DM Pipeline Will Continue to Grow with the Rising Obesity Incidence - Research and Markets

Research and Markets
Posted on: 28 Nov 16

Research and Markets has announced the addition of the "Diabetes & Obesity Drug Development Pipeline Review, 2016" report to their offering.

The diabetes and obesity disease cluster is currently dominated by therapeutics indicated for type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), and the majority of the pipeline, in terms of both quantity and quality of products, is attributable to these indications. While products indicated for obesity do not currently have a large market presence, there are a large number of these products in the pipeline, with the majority in early stages of development.

The combined therapy area of diabetes and obesity presents a strong pipeline, accounting for a large proportion of the overall metabolic disorders therapy area. The majority of products are small molecules and biologics, which reflects the overall pharmacotherapeutic market trend.

An increasing pipeline presence for obesity-indicated products and overwhelming global media interest highlight the relevance of this indication and its future potential global revenues. However, the number of pharmacotherapeutic products for obesity is dwarfed by diabetes-indicated products. Given the status of obesity as a risk factor for T2DM, it is likely that the T2DM pipeline will continue to grow with the rising obesity incidence.

Scope:

  • Which companies are the most active within the pipeline for diabetes and obesity?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared with pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have occurred in this disease area?

Key Topics Covered:

1. Table & Figures

2. Diabetes and Obesity Report Coverage

3. Therapeutics Development by Stage

4. Therapeutics under Development by Companies

5. Therapeutics under Investigation by Universities/Institutes

6. Pipeline Products Glance

7. Products under Development by Companies

8. Products under Investigation by Universities/Institutes

9. Companies Involved in Therapeutics Development

10. Therapeutics Assessment

11. Dormant Projects

12. Discontinued Products

13. Product Development Milestones

14. Appendix

For more information about this report visit http://www.researchandmarkets.com/research/vh5qnj/diabetes_and

View source version on businesswire.com: http://www.businesswire.com/news/home/20161128005766/en/

Business Wire
www.businesswire.com

Last updated on: 28/11/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.